FLGT Form 4: CFO Paul Kim has 671 shares withheld for taxes

Rhea-AI Filing Summary

Fulgent Genetics (FLGT) reported an insider equity transaction by its Chief Financial Officer and Treasurer, Paul Kim. On 11/23/2025, 671 shares of common stock were withheld at a price of $30 per share to cover tax obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly. This filing documents a routine administrative event related to equity compensation rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kim Paul

Role CFO and Treasurer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	671	$30.00	$20K

Holdings After Transaction: Common Stock — 333,447 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
11/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/23/2025		F		671(1)	D	$30	333,447	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

	/s/Paul Kim	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Fulgent Genetics (FLGT) report in this Form 4?

Fulgent Genetics reported that its CFO and Treasurer, Paul Kim, had 671 shares of common stock withheld on 11/23/2025 to satisfy tax withholding obligations from vesting restricted stock units.

Who is the reporting person in this Fulgent Genetics (FLGT) Form 4 filing?

The reporting person is Paul Kim, who serves as CFO and Treasurer of Fulgent Genetics, Inc.

How many Fulgent Genetics (FLGT) shares were involved in the reported transaction?

The transaction involved 671 shares of Fulgent Genetics common stock, which were withheld to cover tax obligations from RSU vesting.

What price per share was used for the Fulgent Genetics (FLGT) tax withholding?

The shares withheld for taxes were valued at $30 per share in the reported transaction.

How many Fulgent Genetics (FLGT) shares does the CFO own after this transaction?

Following the tax withholding, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly.

Was this Fulgent Genetics (FLGT) Form 4 transaction an open-market buy or sell?

No. The filing explains the shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.

What equity award triggered the Fulgent Genetics (FLGT) tax withholding event?

The tax withholding was triggered by the vesting of restricted stock units granted on February 23, 2023, which were originally reported in a prior filing on February 27, 2023.